FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate AJMC FDA Proposes Exclusion of Semaglutide, Tirzepatide, Liraglutide from 503B Bulks List FDA posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Everything You Need to Know About the FDA Peptide Ban BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification